All In Biotech

Drug Trial Radar · NCT07730138

Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants With Gastric Ulcer

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 384 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

384

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Apr 15, 2028

Study completion Oct 15, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer

Conditions

  • Gastric Ulcer

Interventions

  • DWP14012 40mg (Fexuprazan)Drug

    DWP14012 40mg(Fexuprazan) + placebo of Lansoprazole

  • Lansoprazole 30mgDrug

    Lansoprazole 30mg + Placebo of DWP14012 40mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative gastric ulcer healing rate confirmed by upper gastrointestinal endoscopy through Week 8Time frame: Week 8

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • RS Cipto Mangunkusumo

    Jakarta, Indonesia

  • The Catholic University of Korea, Incheon St. Mary'S Hospital

    Incheon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.